AI-generated image
The relationship in one paragraph.
The Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) and the Production Linked Incentive (PLI) Scheme for Bulk Drugs are complementary government initiatives designed to strengthen India's pharmaceutical manufacturing value chain. RPTUAS functions as a technology enablement facility, offering existing Micro, Small, and Medium Enterprises (MSMEs) a 10% to 20% capital subsidy (up to ₹2 Crore) to upgrade their manufacturing facilities to global World Health Organization Good Manufacturing Practices (WHO-GMP) and Schedule M standards [1]. The Bulk Drugs PLI acts as a production-linked booster, providing performance-based financial incentives on incremental sales of key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs) produced in the country [2]. Pharma MSMEs can stack these initiatives by utilizing RPTUAS subsidies to upgrade their facility's compliance, which is a prerequisite for manufacturing high-quality bulk drugs, and then using the upgraded plant to scale production of eligible APIs and claim sales incentives under the Bulk Drugs PLI.
Side-by-side facts.
| Feature | Revised Pharmaceutical Technology Upgradation Assistance Scheme (RPTUAS) [1] | Bulk Drugs PLI Scheme [2] |
|---|---|---|
| Primary Focus | Capital support for technology and compliance upgrades [1] | Sales-linked financial incentives for domestic production [2] |
| Who it's for | Existing pharmaceutical MSMEs with turnover under ₹500 Crore [1] | Approved manufacturers of critical bulk drugs, KSMs, and intermediates [2] |
| Incentive Benefit | 10% to 20% subsidy on plant machinery, capped at ₹2 Crore [1] | 10% to 20% cashback on incremental sales of eligible chemicals [2] |
| Quality Mandate | Requires upgradation to WHO-GMP or Schedule M standards [1] | Production must meet Indian Pharmacopoeia or international standards [2] |
| Compliance Gate | Physical verification and technical audit of upgraded machinery [1] | Quarterly/annual audits of Domestic Value Addition (DVA) and sales [2] |
| Application Process | Online submission of upgrade project reports via SIDBI portal [1] | Application during designated windows; annual incentive claim filing [2] |
Figure 2: RPTUAS & Bulk Drugs PLI technology upgrade and sales incentive integration milestones, eligibility comparison, and certification workflows. [AI Generated]
The recommended order, and why.
For pharmaceutical manufacturing startups and MSMEs, the recommended sequencing is RPTUAS technology upgradation first, then Bulk Drugs PLI incentive claims.
- Conduct Compliance Gap Audit (RPTUAS): Assess your existing plant's machinery, cleanroom design, HVAC systems, and laboratories against the updated Schedule M and WHO-GMP requirements [1].
- Apply for RPTUAS Capital Subsidy: Prepare a detailed project report for the required technology upgrades. Apply through the Central portal to secure a 10% to 20% capital subsidy (up to ₹2 Crore cap) on new eligible machinery and equipment [1].
- Execute Upgrade & Secure GMP Certificate: Complete the physical upgrades and pass the joint inspection by Central and State drug control authorities to obtain your official WHO-GMP compliance certificate [1].
- Scale Production & Claim PLI Incentives: Use the certified facility to manufacture target APIs, key starting materials, or drug intermediates. Once your incremental sales exceed the base-year thresholds, file annual claims under the Bulk Drugs PLI to receive 10% to 20% cashbacks on sales [2].
Common mistakes.
- Applying for PLI incentives with non-compliant facilities: The Bulk Drugs PLI requires production of certified pharmaceutical-grade active inputs [2]. Startups that try to skip RPTUAS technology upgrades often run into quality failures or fail regulatory audits, which automatically disqualifies them from receiving sales incentives [1, 2].
- Buying non-approved machinery under RPTUAS: RPTUAS subsidies only cover specific, energy-efficient, and high-precision machinery defined in the official scheme guidelines [1]. Buying second-hand or non-approved equipment will lead to subsidy rejection during the technical verification stage [1].
- Failing to maintain distinct audit trails: Startups must keep separate accounts for the capital subsidy received under RPTUAS and the sales/DVA audits required for PLI claims. Mixing these funds or failing to provide clean audit trails will cause delays or rejection in incentive disbursements [1, 2].
- Missing the email obfuscation guardrail: When communicating with nodal authorities, use official contact channels. Contact support via rptuas-support [at] sidbi [dot] in or pli-pharma [at] ifciltd [dot] com to prevent public exposure of contact details.
Next step.
Get started with your pharmaceutical manufacturing upgrade:
- Run the Eligibility Wizard to verify if your current turnover and registration status qualify for RPTUAS.
- Explore the Make in India scheme page to discover matching state-level incentives for pharma industrial parks and common facility centers.